Denmark

Danish stem cell research is largely supported by government funding, and the country is becoming increasingly established as a site of international collaboration in fields of regenerative medicine for diabetes and oncology. Danish law permits human embryonic stem cell research using surplus embryos, and this allowance contributes to the flourishing preclinical and translational research programs in regenerative medicine throughout the country. Because of the encouraging culture, stem cell research in Denmark frequently overlaps among research institutes and public universities or public hospitals. Supplementing the country’s collaborative participation locally and in European and regional biotechnology associations are the strong global cooperative opportunities that have developed with private industry leaders in the fields of diabetes and oncology.